Which pharmaceutical company makes Mounjaro — and why it matters

How Eli Lilly brought tirzepatide from the laboratory to UK pharmacies

Eli Lilly was founded in Indianapolis in 1876 and has a long record in metabolic medicine, it was among the first companies to manufacture insulin at commercial scale in the 1920s. Tirzepatide, the molecule at the heart of Mounjaro, is a newer chapter in that history. Lilly's researchers designed it as a single peptide capable of binding to both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing a combined effect on appetite, blood-sugar regulation and gastric emptying that neither pathway achieves alone.

The UK marketing authorisation was granted by the MHRA following the SURMOUNT clinical programme. SURMOUNT-1, the pivotal weight-management trial, randomised 2,539 adults with obesity and ran for 72 weeks. At the highest dose, participants lost an average of around 20–21% of body weight, figures that informed NICE's appraisal of tirzepatide (TA1026), published in December 2024. Lilly supplies Mounjaro to the UK through its authorised distribution network; nume sources treatment through that licensed UK supply chain. If you want to understand how the underlying science compares with other agents, the tirzepatide overview on our site walks through the mechanism in plain language.

Mounjaro carries a Black Triangle designation in the UK. That symbol, printed on the packaging, signals that the MHRA expects Lilly to conduct additional post-market surveillance and report data on a rolling basis. It is standard for newer medicines and does not mean the product is considered unsafe, it means the regulator is watching closely, which is exactly what you want.

What the dual-agonist mechanism actually does, and what the trial data showed

GLP-1 agonists like semaglutide slow gastric emptying and reduce appetite by signalling through one receptor. Tirzepatide adds a second signal through the GIP receptor, and the combination appears to produce greater average weight loss than GLP-1 stimulation alone. The SURMOUNT-1 results, published in the New England Journal of Medicine, reported average body-weight reductions of roughly 15% at 5mg, 19.5% at 10mg and around 20–21% at 15mg over 72 weeks. These are mean figures from a clinical trial population; individual results vary, and Mounjaro is always used alongside a reduced-calorie diet and increased physical activity.

SURMOUNT-5, a head-to-head trial reported in the NEJM in 2025, compared tirzepatide directly with semaglutide 2.4mg in 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction in that study. NICE's TA1026 committee noted that indirect comparisons also favour tirzepatide, while acknowledging that the newer, higher-dose semaglutide 7.2mg pen narrows the gap. None of this settles which medicine suits a given individual, that is a clinical question, not a league-table one. Our page on how Lilly structures the Mounjaro programme goes into further detail on the approvals history.

Treatment starts at 2.5mg, a dose whose job is letting your system adjust, not producing immediate weight loss. The prescriber then titrates upward, typically in four-week steps, through 5mg, 7.5mg, 10mg, 12.5mg and up to 15mg. Dosing decisions belong to the prescriber and the Patient Information Leaflet; this page describes the schedule only as context.

Eli Lilly's UK supply relationship and what that means for legitimacy

Knowing who manufactures a medicine matters when you are buying it through a private pharmacy. Counterfeit tirzepatide pens have been seized in the UK: in October 2025, the MHRA raided what it described as the first illicit manufacturing site producing fake tirzepatide pens on UK soil, in Northampton, as part of enforcement that has recovered roughly 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million. The fakes circulate through social media sellers and websites offering these medicines without a prescription, a reliable red flag.

Legitimate supply runs through Eli Lilly's authorised UK distribution chain, reaching patients only via a valid prescription from a regulated prescriber. For context on what private treatment costs and what that price typically covers, our Mounjaro cost guide is a useful starting point. You can verify any online pharmacy's registration on the GPhC pharmacy register before placing an order, that takes about thirty seconds and is worth doing. The background on Mounjaro's pharmaceutical development covers Lilly's regulatory submissions in more depth.

Some readers ask about Viogen Pharmaceuticals and tirzepatide, a separate question about a different company name that sometimes appears in searches. The answer to who holds the UK marketing authorisation for Mounjaro is straightforward: it is Eli Lilly. The what company makes Mounjaro page and the tirzepatide drug company page both address related angles if you want the fuller picture of Lilly's regulatory position.

At nume, our clinical team reviews every consultation personally, a GPhC-registered Independent Prescriber reads your answers the same day. No algorithm makes the call. If you are exploring whether Mounjaro is right for you, a look at our weight-loss treatment overview is a sensible next step before booking.